What is Zacks Research's Estimate for Surmodics Q3 Earnings?

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Stock analysts at Zacks Research issued their Q3 2025 earnings estimates for Surmodics in a research note issued on Wednesday, May 21st. Zacks Research analyst D. Dey expects that the company will post earnings per share of ($0.18) for the quarter. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics' Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.44) EPS, Q1 2026 earnings at ($0.11) EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.06 EPS, FY2026 earnings at ($0.01) EPS, Q1 2027 earnings at $0.02 EPS and Q2 2027 earnings at $0.12 EPS.

A number of other research firms have also weighed in on SRDX. Lake Street Capital raised shares of Surmodics from a "hold" rating to a "buy" rating and set a $43.00 target price for the company in a report on Friday, March 7th. Needham & Company LLC reissued a "hold" rating on shares of Surmodics in a research note on Wednesday, April 30th. Finally, Wall Street Zen initiated coverage on shares of Surmodics in a research report on Monday, February 3rd. They set a "hold" rating on the stock. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $43.00.

Surmodics Price Performance

NASDAQ SRDX traded up $0.11 during trading hours on Monday, reaching $28.81. The company's stock had a trading volume of 33,782 shares, compared to its average volume of 278,740. Surmodics has a 1 year low of $26.00 and a 1 year high of $42.44. The company has a quick ratio of 4.29, a current ratio of 5.45 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $411.95 million, a price-to-earnings ratio of -28.52 and a beta of 1.32. The firm's 50-day moving average price is $28.79 and its 200-day moving average price is $33.72.

Surmodics (NASDAQ:SRDX - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.07). Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%. The company had revenue of $28.09 million during the quarter, compared to the consensus estimate of $32.23 million.

Institutional Investors Weigh In On Surmodics

A number of institutional investors and hedge funds have recently modified their holdings of SRDX. Murchinson Ltd. boosted its holdings in Surmodics by 5.8% in the first quarter. Murchinson Ltd. now owns 52,981 shares of the company's stock valued at $1,618,000 after purchasing an additional 2,900 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Surmodics by 71.6% in the first quarter. Millennium Management LLC now owns 206,487 shares of the company's stock worth $6,304,000 after buying an additional 86,143 shares during the last quarter. Alpine Global Management LLC grew its holdings in Surmodics by 70.0% during the first quarter. Alpine Global Management LLC now owns 85,000 shares of the company's stock worth $2,595,000 after acquiring an additional 35,000 shares during the period. Angelo Gordon & CO. L.P. raised its position in Surmodics by 60.0% during the first quarter. Angelo Gordon & CO. L.P. now owns 40,000 shares of the company's stock valued at $1,221,000 after acquiring an additional 15,000 shares in the last quarter. Finally, GABELLI & Co INVESTMENT ADVISERS INC. raised its position in Surmodics by 51.2% during the first quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 195,387 shares of the company's stock valued at $5,965,000 after acquiring an additional 66,150 shares in the last quarter. Institutional investors and hedge funds own 96.63% of the company's stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).